SHPH Bathi pungkasan Shuttle Pharmaceuticals Holdings, Inc.

The credit rating potential of Shuttle Pharmaceuticals (SHPH) is based on the sale of radiosensitizers to oncology centers. The company's final financial result demonstrates a stable price range, where the parameter value equals -0.01. Capital stability is ensured by outsourcing drug synthesis through cGMP partners, while overall solvency relies on the trial results of small molecules that remain independent of external macroeconomic fluctuations.

The specific nature of Shuttle Pharmaceuticals (SHPH), with its focus on early-stage testing of oncosensitizers, makes net profit a critical indicator of the company's ability to fund academic alliances without external borrowing. When analyzing the company's net cash flow, an investor must strip out loss-making assets, keeping in mind that even a profitable status at peak valuation does not guarantee protection against a subsequent deep drawdown in share prices.